Spruce Biosciences, INC DEF 14A proxy statements

Spruce Biosciences, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for May 21, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Spruce Biosciences, Inc. has received conditional approval from Nasdaq to resume trading on the Nasdaq Capital Market, contingent upon stockholder approval of a reverse stock split to meet minimum bid price requirements by August 5, 2025.

Spruce Biosciences, Inc. has announced its 2025 Annual Meeting of Stockholders, where key proposals include the election of three Class II directors, ratification of its independent auditor, and a significant reverse stock split ranging from 1-for-50 to 1-for-100.

Spruce Biosciences, Inc. has announced a supplement to its proxy statement, delaying its annual meeting to July 22, 2025, and proposing a significant reverse stock split to address its Nasdaq delisting and critical financial viability concerns.

Spruce Biosciences is holding its annual stockholder meeting on June 9, 2025, to vote on director elections, auditor ratification, a potential reverse stock split, and adjournment if necessary.

Spruce Biosciences seeks stockholder approval for a reverse stock split to meet Nasdaq's minimum bid price requirement and facilitate future financing.

Spruce Biosciences has scheduled its 2024 Annual Meeting for May 22, 2024, and is seeking stockholder votes on the election of directors and ratification of the company's independent auditor.

Spruce Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on May 22, 2024, to elect directors and ratify the selection of its independent accounting firm.